Alnylam launches hereditary attr (hattr) amyloidosis campaign to help shorten time to diagnosis for inherited and rapidly progressive disease

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced the launch of the family health history road trip, its program designed to encourage conversations between family members about their health history so they can discuss with their doctor to better understand their risk for developing an inherited disease like hereditary attr (hattr) amyloidosis. inspired by the traditional family road trip, the program follows.
ALNY Ratings Summary
ALNY Quant Ranking